MPC Therapeutics

🚀 Exciting News! 🚀 Tomorrow, our CEO Raphaël Martinou will be attending the #CAR-TCR Summit in London! This is a fantastic opportunity to connect, exchange insights, and introduce our latest innovation: MitoStemX – a universal media supplement designed to enhance the fitness and stemness of CAR-T cells. If you're attending, let’s connect and discuss how MitoStemX can help improve your CAR-T therapies! 💡 #CARTCRSummit #CellTherapy #Immunotherapy #MitoStemX #CART #Biotech #Innovation

Today our CTO Mathias Wenes is presenting at European Hematology Association (EHA) / The EBMT European CAR-T meeting in Strasbourg, alongside the best researchers and clinicians in the field. Join his session to hear the latest news from MitoStemX, our therapeutic T-cell enhancement technology program! It's at 2pm in the Translational Research session. #CAR25 #Tcell #immunometabolism

🚀 We’re thrilled to announce our latest publication highlighting the impact of our lead asset, MITO-66, on CAR-T cell therapies! MITO-66 enhances T cell therapies by making them more effective, more durable, and it outperforms other small molecule enhancers used in CAR-T treatments. 👏 Huge congratulations to our fantastic team for their dedication and hard work—especially our CTO Mathias Wenes, CSO Jean-Claude Martinou, and close advisors Denis Migliorini, M.D. and Pedro Romero along with former postdoc Anouk Lepez ! Since submitting this work, we’ve developed the second-generation of our technology, designed to push the boundaries of CAR-T effectiveness even further. If you’re interested in testing this new iteration, feel free to reach out—we’d love to collaborate and help you elevate your T cell therapies to the next level ! https://lnkd.in/e_StZSuy

Great team meeting at the fantastically located, equipped and decorated PepperHub - Centre d'affaires in Gland! Thanks Jean Philippe KUNZ for the invitation!

After one decade of CD19-CAR T cell therapy, this paper determined for the first time the characteristics of the CAR T cell therapeutic product inducing very long-term (> 8 years) remission. They found that beyond a T helper 2 signature, a memory gene signature significantly correlates with durable remission. S The good news, is that at MPC Therapeutics, we are working to improve precisely these markers in CAR-T preparations. We aim to enrich therapies with stem cell-like and central memory T-cells, which play a key role the persistence and durable efficacy of cell therapies. In the coming months, we will reach out to our partners to propose our latest technology, MitoStemX, for evaluation and licensing…   Stay tuned... More to follow   Congratulations to the authors for their recent publication in Nature. https://lnkd.in/e2CPGGyN

Meet our team in the road this month! - This Thursday and Friday Raphaël Martinou and Augustin de Bettignies will at MATWIN's #MeettoWin congress in Bordeaux. We'll showcase our latest results in the poster session on Thursday evening - Wednesday 22nd, we'll be at the first edition of "Innovation in Cell and Gene Therapy" summit organised by MabDesign Network and SFTCG-French Society for Cell and Gene Therapy in Paris. - Thursday 30th and Friday 31st, our CTO Mathias Wenes will be opening the VIB Recent insights in #ImmunoOnco2024 in Leuven. We look forward to interacting with you there and then!

We will be sharing our latest results at the MATWIN congress in May. It's a great place for oncology startups to connect with industry and investment professionals... We hope to see you there!

Donor-to-donor variability has long been recognized as a challenge in cell therapy. However, it's crucial to recognize that manufacturing systems also play a significant role in shaping cell therapy products. Check this insightful paper from the NIH looking at how leading systems, and cellular oxygenation in particular, influence cell expansion, phenotypes & metabolism. Congrats to all the authors ! cc Hannah W. Song Steven Highfill https://lnkd.in/epjn5GPu

Join us today at 12:40 at the CAR-TCR Summit in London! Our CTO, Mathias Wenes will be taking the stage to present how MITO-66, our novel small molecule targeting metabolism, enhances the fitness and durability of CAR T cells against cancer. Join us for his presentation and feel free to connect with us afterward if you'd like to learn more about our innovative science. See you there ! #cartcelltherapy #cancertreatment #mitochondria